Ocular Therapeutix. has filed a patent for an intracameral implant that can treat ocular diseases in humans. The implant consists of a biodegradable hydrogel containing polyalkylene glycol units and travoprost particles, which are dispersed within the hydrogel. This sustained release implant could potentially provide a new treatment option for ocular diseases. GlobalData’s report on Ocular Therapeutix gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ocular Therapeutix, Nanoparticle drug conjugates was a key innovation area identified from patents. Ocular Therapeutix's grant share as of September 2023 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Intracameral implant for treating ocular diseases
A recently filed patent (Publication Number: US20230285281A1) describes an intracameral implant for the treatment of ocular hypertension and/or glaucoma. The implant consists of a biodegradable hydrogel containing travoprost particles, which are dispersed within the hydrogel. The hydrogel is made up of a polymer network that includes polyalkylene glycol units. The implant has a length of 1.00 mm to 2.50 mm and a diameter of not more than 0.30 mm in its dried state. After 24 hours of hydration in vitro, the implant has a diameter of less than 0.50 mm. The ratio of the diameter of the hydrated implant to the diameter of the dried implant is less than 2.5. The implant contains a dose of 2 µg to 30 µg of travoprost. The biodegradable polymer in the implant is a polylactide. The hydrogel also includes polyethylene glycol units. The implant can be in the form of a fiber and has a total weight of 20 µg to 110 µg in its dried state. The implant shows a burst of less than 15% on day 1, based on the total weight of travoprost, under simulated physiological sink conditions. The total mass of the biodegradable polymer in the implant is less than 34 µg. The total mass of travoprost in the implant is less than 25 µg. The total mass of the implant is less than 103 µg in its dried state. The travoprost particles have a diameter ranging from 1 to 100 µm. The polymer network of the hydrogel is formed by reacting an electrophilic group-containing multi-arm-polymer precursor with a nucleophilic group-containing cross-linking agent. The implant can be used to treat intraocular pressure in a human subject for a period ranging from 1 to 24 months with one single implant per eye. The patent also describes methods of manufacturing the implant and a syringe for intracameral injection containing the implant.
To know more about GlobalData’s detailed insights on Ocular Therapeutix, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
